



BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN
-------------	------------	-------------------	-------------------

Lupin appoints Paul McGarty as President for Lupin Pharmaceuticals Inc.

Mumbai, August 03, 2010: Lupin Ltd. today announced the appointment of Paul McGarty as President of its US Subsidiary, Lupin Pharmaceuticals, Inc. Paul has over 25 years experience in the Pharmaceutical Industry spanning across brand and specialty pharmaceutical companies.

Most recently, as the CEO of Nycomed US, Paul successfully transformed the company from a topical manufacturer into a Dermatology Specialty Company with a brand & generic business. Under his leadership Nycomed US emerged as a leading fully integrated Dermatology Specialty company in the US.

Paul received his BS degree in Chemical Engineering from the University of Rhode Island and holds an MBA from PACE University in NY. Paul has also served as a member of the Executive Committee and Board of Directors for the Generic Pharmaceutical Association (GPhA), as well as a member of the National Association of Chain Drug Stores (NACDS) Foundation board.

Commenting on the appointment, Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., said, "I am very pleased to welcome Paul as the President for our US subsidiary, Lupin Pharmaceuticals, Inc. With more than 25 years of experience in pharmaceutical operations as well as commercial functions, in both generic and branded business, Paul brings invaluable experience and leadership skills to Lupin's growth plans in the US".

About Lupin Limited

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant presence in Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Today, Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing, top 10 Generic players in Japan and South Africa. (IMS)

For the financial year ended March 2010, Lupin's Consolidated Sales and Profit after Tax were Rs.47,678 million (USD 1.1 Billion) and Rs. 6816 million (USD 138 Million) respectively.

For further information please contact:

Shamsher Gorawara

Lupin Limited:

Ph: +91 98 20 338 555

Email: shamshergorawara@lupinpharma.com or

Sonia Mansatta

Text 100 Public Relations

Ph: +91 98 20 11 2481

Email: sonia.mansatta@text100.co.in